Donald Jackson
About Donald Jackson
Donald Jackson is the Director of Translational Bioinformatics Cambridge at Bristol-Myers Squibb and the Head of Precision Oncology Bioinformatics at Sanofi, with extensive experience in biomarker discovery and target validation in oncology and immuno-oncology.
Current Positions
Donald Jackson currently holds prominent roles at two renowned pharmaceutical companies. He is the Head of Precision Oncology Bioinformatics at Sanofi, based in Cambridge, Massachusetts. Additionally, he serves as the Director of Translational Bioinformatics Cambridge at Bristol-Myers Squibb, also in Cambridge, MA. His key responsibilities include leading bioinformatics efforts aimed at precision oncology, with a special focus on biomarker discovery and validation.
Previous Roles and Experience
Donald Jackson has accumulated substantial experience over a career spanning decades. He worked at Bristol-Myers Squibb from 1999 to 2020, holding titles such as Principal Scientist and Research Fellow in Translational Bioinformatics in Princeton, NJ. Before Bristol-Myers Squibb, he spent two years as a Postdoctoral Fellow at Massachusetts General Hospital and two years as a Research Technician at Johns Hopkins School of Medicine. These roles significantly contributed to his expertise in oncology and immuno-oncology.
Academic Background
Donald Jackson obtained his PhD from The Johns Hopkins University School of Medicine, where he studied Biochemistry, Cellular and Molecular Biology from 1990 to 1997. His rigorous academic training laid a solid foundation for his future work in bioinformatics, particularly in target discovery and target validation, areas where he has since excelled.
Expertise in Bioinformatics
Donald Jackson has extensive expertise in the field of bioinformatics, with specialized knowledge in biomarker discovery, especially for oncology and immuno-oncology. His work involves target discovery and target validation, making substantial contributions to advancing precision oncology. His expert knowledge facilitates improved understanding and treatment of various types of cancer.